Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Primary Care Strategies to Reduce High Blood Pressure: A Cluster Randomized Trial in Rural Bangladesh, Pakistan and Sri Lanka (COBRA-BPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02657746
Recruitment Status : Enrolling by invitation
First Posted : January 18, 2016
Last Update Posted : October 31, 2019
Sponsor:
Collaborators:
International Centre for Diarrhoeal Disease Research, Bangladesh
Aga Khan University
University of Kelaniya
Information provided by (Responsible Party):
Professor Tazeen Jafar, Duke-NUS Graduate Medical School

Brief Summary:

Background: High blood pressure (BP) is the leading attributable risk for cardiovascular disease (CVD). In rural South Asia, hypertension remains to be a significant public health issue with sub-optimal rates of case finding and management. The goal of the full-scale study is to evaluate the effectiveness and cost-effectiveness of multicomponent primary care strategies on lowering blood pressure among adults with hypertension in rural communities in Bangladesh, Pakistan, and Sri Lanka.

Methods/Design: The mixed-methods, stratified cluster randomized controlled trial

Intervention: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.

Usual care: Will comprise existing services in the community without any additional training.

Participants: The trial will be conducted on 2550 individuals aged 40 years or older with hypertension (systolic BP ≥ 140 mm Hg or diastolic BP≥ 90 mm Hg, or on antihypertensive therapy) in 30 rural communities of Bangladesh, Pakistan and Sri Lanka. Out of the 2550 individuals, 420 with poorly controlled BP (Systolic BP≥160 mmHg or Diastolic BP≥100 mmHg) will be selected, 14 from each community, to investigate the effect of MCI on results from ambulatory BP monitoring.

Qualitative component: Stakeholders including policymakers, district managers, and community health workers, GPs, hypertensive individuals and family members in the identified clusters will be surveyed.

Outcome: The primary outcome will be change in systolic BP from baseline to follow-up at 24 months post randomization. The cost effectiveness outcome is the incremental cost of MCI per unit reduction in BP over the two year time period and in terms of incremental cost per CVD DALYs averted.


Condition or disease Intervention/treatment Phase
Hypertension Other: multi-component interventions Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2550 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Control of Blood Pressure and Risk Attenuation-Bangladesh, Pakistan and Sri Lanka (COBRA-BPS)
Actual Study Start Date : May 1, 2016
Actual Primary Completion Date : March 2019
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: usual care
Usual care comprises existing services for hypertension control in the community without any additional training
Experimental: multi-component interventions
: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
Other: multi-component interventions
The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.




Primary Outcome Measures :
  1. Blood pressure reading:change in systolic blood pressure (SBP) from baseline to follow-up at 24 months post randomization. [ Time Frame: Blood pressure (BP) will measured at baseline and then at 6-month intervals until 24 months after randomization ]

Secondary Outcome Measures :
  1. Blood pressure reading:Blood Pressure(BP) controlled to target (Systolic BP <140 mm Hg and Diastolic BP <90 mm [ Time Frame: at 6-month intervals over 24 months ]
  2. Questionnaire:Composite outcome of death (all cause), or hospital admission due to coronary heart disease (CHD), heart failure, or stroke [ Time Frame: 24 months ]
  3. Questionnaire and EQ-5D-5L:Incremental cost per quality-adjusted life-year (QALY) gained from baseline to end of follow-up [ Time Frame: 24 months ]
  4. Morisky Medication Adherence Scale(MMAS):Change in antihypertensive medication adherence (Morisky score) [ Time Frame: 24 months ]
  5. Height and weight measurements:change in body mass index ( BMI) [ Time Frame: 24 months ]
  6. questionnaire:change dietary salt intake (urinary excretion) [ Time Frame: 24 months ]
  7. Questionnaire:change in prevalence of current smokers [ Time Frame: 24 months ]
  8. Questionnaire:incident diabetes [ Time Frame: 24 months ]
  9. Lipid panel: change in serum lipid levels [ Time Frame: 24 months ]
  10. questionnaire: change in INTERHEART cardiovascular disease (CVD) risk score [ Time Frame: 24 months ]
  11. Questionnaire:incidence of adverse outcomes (medication side effects, sick days absenteeism, low QALY between randomized groups). [ Time Frame: 24 months ]
  12. Questionnaire and serum creatinine:Change in estimated glomerular filtration rate (eGFR) [ Time Frame: 24 months ]
  13. Urine albumin:Change in urine albumin [ Time Frame: 24 months ]
  14. 24 hours mean diastolic BP [ Time Frame: 24 months ]
    Secondary outcome for the sub-study of 420 patients with poorly controlled BP at baseline

  15. Daytime SBP/DBP [ Time Frame: 24 months ]
    secondary outcome for the sub-study of 420 patients with poorly controlled BP at baseline

  16. Night time SBP/DBP [ Time Frame: 24 months ]
    Secondary outcome for the sub-study of 420 patients with poorly controlled BP at baseline

  17. Dipping Pattern [ Time Frame: 24 months ]
    Secondary outcome for the sub-study of 420 patients with poorly controlled BP at baseline

  18. 24 hour BP variability [ Time Frame: 24 months ]
    Secondary outcome for the sub-study of 420 patients with poorly controlled BP at baseline

  19. Questionnaire and EQ-5D-5L:Incremental cost per mm Hg BP reduction from baseline to end of follow-up at two years post randomization and incremental cost per projected cardiovascular disease ( CVD) disability adjusted life year (DALY) averted [ Time Frame: information on healthcare cost will be collected at baseline and 24 months ]
  20. incremental cost per mm Hg BP reduction from baseline to end of follow-up at 2 years post-randomization and incremental cost per projected CVD disability-adjusted life year (DALY) averted [ Time Frame: 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main study:

Inclusion Criteria:

  1. Age≥ 40 years
  2. Residing in the selected clusters
  3. Hypertension defined either as:

    1. Persistently elevated BP (systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg) from each set of last 2 of 3 readings from 2 separate days
    2. maintained on anti-hypertensive medications
  4. Informed consent

Exclusion Criteria:

  1. Permanently bed-ridden individuals too ill to commute to the clinic
  2. Pregnancy, or individuals with advanced medical disease (on dialysis, liver failure, other systemic diseases)
  3. Individuals that are mentally compromised and unable to give informed consent

Sub-study:

1) fulfill all criteria of main study and, 2) Persistently elevated systolic BP >160 mm Hg or diastolic BP >100 mm Hg from each set of 2 readings from 2 separate days

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02657746


Sponsors and Collaborators
Duke-NUS Graduate Medical School
International Centre for Diarrhoeal Disease Research, Bangladesh
Aga Khan University
University of Kelaniya
Investigators
Layout table for investigator information
Principal Investigator: Tazeen H Jafar, MD,MPH Duke-NUS Medical School (Singapore)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Professor Tazeen Jafar, Professor, Duke-NUS Graduate Medical School
ClinicalTrials.gov Identifier: NCT02657746     History of Changes
Other Study ID Numbers: MR/N006178/1
First Posted: January 18, 2016    Key Record Dates
Last Update Posted: October 31, 2019
Last Verified: October 2019
Keywords provided by Professor Tazeen Jafar, Duke-NUS Graduate Medical School:
blood pressure monitoring
high blood pressure
cardiovascular disease
Antihypertensive agents
Non-pharmacological treatment
community health care workers
cost-effectiveness
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases